In the LIPO-010 trial, a randomized, double-blind, placebo-controlled study, tesamorelin reduced visceral adipose tissue by 19.6% over 26 weeks compared to placebo
The US Food and Drug Administration approved semaglutide in 2017 to improve the control of blood sugar levels in adults with type 2 diabetes and then, in June 2021, for chronic weight management in adults who are obese or overweight and have related risk factors, such as high blood pressure or diabetes
This one pairs especially well with the lighter meals typical of tirzepatide users
Others claim it supports gut health, recovery, or even neurological repair
NICE-appraised licensed alternatives such as semaglutide (Wegovy) and liraglutide (Saxenda) are available through regulated UK weight management services